Clinical significance of HIF-2α immunostaining area in radioresistant cervical cancer by Kim, Min Kyu et al.
INTRODUCTION
Radiation therapy with or without cisplatin-containing 
chemotherapy is the most commonly used treatment mo-
dality in patients with advanced cervical cancer [1]. However, 
recurrence after radiotherapy remains a problem in the 
treatment of locally advanced cervical cancer. Therefore, a 
study focusing on the molecules affecting radioresistance is 
important to determine the mechanism underlying radio-
resistance.
Hypoxia has been established as a key factor influencing 
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Objective: Hypoxia has been established as a key factor influencing the pathophysiology of malignant growth. Hypoxia-induced 
changes in gene expression are coordinated primarily by hypoxia inducible factor-1 alpha (HIF-1α) and HIF-2α. The purpose of 
this study was to determine whether or not HIF-2α expression is associated with survival and response to radiation in patients 
with cervical cancer.
Methods: After reviewing the medical records of 119 patients treated in our institution by primary therapy for stage IIB-IVA 
cervical cancer, we performed a case-control study. Cases (n=12) were selected from patients with local recurrence or radiation 
failure after primary radiation therapy with or without concurrent chemoradiation. For each case, we selected two controls from 
patients who had no evidence of local recurrence. Using pre-treatment paraffin-embedded tissues, we evaluated the expression 
of HIF-2α by immunohistochemistry. Staining was scored based on intensity (intensity score [IS], 0-3) and proportion (proportion 
score [PS], 0-100). The results were analyzed by the Student t-test, Mann-Whitney U test, Fisher’s exact test, and Cox proportional 
hazards regression model.
Results: Cytoplasmic expression of HIF-2α, representing the degree of hypoxia, had a relationship with poor response to 
radiotherapy. The hazard ratio of recurrence was 1.71 for the HIF-2α IS (p=0.110) and 1.04 for the HIF-2α PS (p<0.001), 
indicating that the HIF-2α staining area correlates weakly with the risk for recurrence.
Conclusion: The HIF-2α expression area may have an important role in radioresistance in patients with locally advanced cervical 
cancer. We conclude that a wider area of hypoxia predicts an increased probability of radioresistance.
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the pathophysiology of malignant growth. Most measurable 
solid tumors, which consume a large amount of oxygen, 
have regions with inefficient vascular supplies. Such low-
oxygen regions have a poorer prognosis and worse response 
to treatment than better oxygenated tumors. Tumor hy  poxia 
is known to be an important factor associated with chemo-
resistance and radioresistance [2-4].
Hypoxia is associated with radiation therapy because 
depletion of oxygen disturbs radiolysis of H2O and reduces 
the production of reactive and cytotoxic species, and because 
radiation-induced DNA damage is fixed and irreparable under 
normoxia [5,6]. Members of the hypoxia inducible factor (HIF) 
family of transcription factors regulate the cellular response 
to hypoxia. There have been several studies regarding HIF-1α 
and radioresistance [7,8]. On the contrary, there have been 
few studies regarding HIF-2α. Moreover, the results are con-
flicting.
HIF-1α and HIF-2α have contrasting roles, as evidenced 
by the opposing regulation of c-Myc [9]. Moeller et al. [10] re-
ported that HIF-1α stimulates p53 phosphorylation and p53-
dependent cell death in cancer cells. Conversely, Bertout et 
al. [11] demonstrated that HIF-2α inhibition promotes p53 
activity.
A clinical study of radiation treatment for head and neck 
cancers reported that the levels of both HIF-1α and HIF-2α 
correlate with radiation resistance [8]. However, in experiments 
by Palayoor et al. [12], transfection of von Hippel-Lindau 
(VHL) into renal cell carcinoma lacking this gene did not alter 
radiation sensitivity, despite leading to an increase in protein 
levels for HIF-1α and HIF-2α. A recent study conducted by 
Franovic et al. [13] showed that HIF-2α has a greater role in 
tumorigenesis than HIF-1α via deactivation of select receptor 
tyrosine kinases, including epidermal growth factor receptor 
(EGFR) and insulin-like growth factor 1 receptor (IGF1R), as 
well as downstream extracellular-regulated kinase (ERK)/Akt 
signaling.
It has been reported that overexpression of HIF-1α in 
uterine cervical cancer cells prior to treatment serves as a 
predictive marker for poor prognosis following treatment by 
radiotherapy [7,14-16]. Recently, the same results regarding 
HIF-2α have been released showing that HIF-2α expression 
is associated with prognosis in patients with cervical cancer 
undergoing radiotherapy [17].
In this study, we evaluated HIF-2α expression in patients 
with locally advanced cervical cancer using immunohistoche-
mistry, and correlated HIF-2α staining with local recurrence 
or failure to respond to radiation treatment. 
MATERIALS AND METHODS
1. Patient selection
According to the availability of cancer tissue, we identified 
119 patients with locally advanced stage IIB-IVA cervical 
cancer who completed primary radiotherapy in the Depart-
ment of Radiation Oncology at Samsung Medical Center of 
Sungkyunkwan University School of Medicine between 1994 
and 2004. We reviewed charts according to Institutional 
Review Board guidelines and performed a case-control study. 
Cases (n=12) were selected from patients with local re  cur-
rence or radiation failure after primary radiation therapy, and 
constituted the radioresistant group. Age-matched con  trol 
patients were selected who had no local recurrence for at 
least 3 years after radiation therapy, which constituted the 
radiosensitive group (n=24). Slides were prepared from stored 
pre-treatment paraffin-embedded tissue blocks from the 36 
patients. 
External beam radiotherapy (EBRT) and high-dose rate (HDR) 
intracavitary brachytherapy [18] were completed according 
to schedule. The whole pelvis total dose was 50.40 gray (Gy) 
with 1.8 Gy daily fractions administered 5 times a week. HDR 
brachytherapy was started 4-5 weeks after initiation of EBRT. 
The dose of HDR brachytherapy was 24 Gy at point A, with 
4 Gy per fraction twice a week for 3 weeks. Progression-free 
survival (PFS) was defined from the end of treatment to the 
day of recurrence by imaging studies or biopsies.
2. Immunohistochemical staining
Sections (6-μm thick) were deparaffinized with xylene, 
rehydrated, and incubated with fresh 0.3% hydrogen peroxide 
in methanol for 30 minutes at room temperature. Specimens 
were rehydrated through a graded ethanol series and washed 
in phosphate-buffered saline (PBS). After a blocking treatment, 
the specimens were incubated with anti-HIF-2α antibody 
(Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) at a 
dilution of 1:200 in PBS containing 1% bovine serum albumin 
(BSA) at 4
oC overnight. Sections were then washed with PBS 
and incubated in secondary antibody for 30 minutes at room 
temperature. The tissue sections were lightly counterstained 
with hematoxylin, then examined by light microscopy. There 
was no detectable staining in negative controls, which were 
prepared by omitting the primary antibody [19]. 
3. Evaluation
Two examiners without knowledge of the clinical outcome 
evaluated the staining. One gynecologic pathologist (COS) 
and one gynecologic oncologist (TJK) reviewed the blinded 
slides and evaluated the immunohistochemical data Min Kyu Kim, et al.
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independently. 
Staining intensity was scored from 0-3, as follows: 0, no 
appreciable staining in the tumor cells; 1, barely detectable 
staining in the cytoplasm, nucleus, or membrane compared 
with stromal elements; 2, readily detectable brown staining 
distinctly marking the tumor cell cytoplasm, nucleus, or mem-
brane; and 3, dark brown staining in tumor cells com  pletely 
obscuring the cytoplasm, nucleus, or membrane [20]. The 
staining was scored based on intensity (intensity score [IS], 
0-3) and proportion (proportion score [PS], 0-100) (Fig. 1).
4. Statistical analysis
We used SAS ver. 9.1.3 (SAS Institute Inc., Cary, NC, USA) for 
statistical calculations. For continuous variables, we used the 
t-test for variables that were normally distributed and the 
Mann-Whitney U test for variables that were not normally 
distributed. Fisher’s exact test was performed for categorical 
variables. To evaluate the relationship of HIF-2α staining to 
PFS, we used a Cox proportional hazards regression model.
RESULTS
The patient characteristics are described in Table 1. The 
median follow-up for the patients studied was 49 months. At 
the time of analysis, all case patients had succumbed from 
causes related to cervical cancer, and all control patients were 
alive with no evidence of recurrence. 
There were no statistical differences in age, cell type, and 
International Federation of Gynecology and Obstetrics 
(FIGO) stages between the two groups. Fig. 1 shows the 
examples of cellular distribution of HIF-2α staining. The 
results of immunohistochemical expression of HIF-2α in 36 
cervical squamous cell carcinomas (12 radioresistant and 24 
radiosensitive) are summarized in Tables 2-4. The expression 
of HIF-2α was significantly more frequent between one 
and two stainings in both groups (Table 2). But we showed 
that the IS (p=0.133), unlike the PS, did not have a close 
relationship with survival in the case group (Table 3).
Intensity shows degree or severity of staining, and pro-
portion means area or boundary of staining. Therefore PS 
more accurately represented the hypoxic area in tumors re-
garding risk of recurrence (Table 4).
Average PS were 20±40 (radiation-resistant group) and 10
Fig. 1. Proportion score and intensity score examples of hypoxia inducible factor-2α expression (x200). A: 0 (0), B: 1 (1), C: 30 (2), D: 90 (3).HIF-2α in radioresistant cervical cancer
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±17 (radiation-sensitive group) (p<0.05).
The PFS of all patients was analyzed based upon HIF-2α 
expression. The median PFS was 9 months for patients in the 
radioresistant group and 73 months for the radiosensitive 
group. The hazard ratio of recurrence was 1.525 for HIF-2α PS 
(p<0.05) (Table 4), indicating that HIF-2α PS correlates weakly 
with recurrence risk and is a pathologic prognostic factor.
DISCUSSION
In the current study, HIF-2α expression was evaluated in 
patients with locally advanced cervical cancer prior to treat-
ment with primary radiotherapy, with a positive association 
between HIF-2α expression in terms of PS and local recur-
rence or radiation failure. In addition, the correlation between 
the area of staining with the risk of recurrence correlated with 
prognosis in patients with cervical cancer. With 10 unit increase 
of PS, risk of recurrence increases 1.525 times more than lower 
unit. Based on the data shown in Tables 3 and 4, we conclude 
that a wider area of hypoxia increase the probability of radio-
resistance. With regard to PS, it appears that the stained area 
represents a more hypoxic than other area. Although we did 
not know the exact mechanism of radioresistance, it may pro-
vide some hint with regard to the relationship with oxygen 
and radiation.
According to a previous study regarding HIF-1α with radi-
ation, it promotes tumor vasculature radioresistance through 
the release of proangiogenic cytokines such as VEGF [21]. 
HIF-2α is the second HIF family member to be identified and 
shares approximately 48% amino-acid sequence homology 
with HIF-1α. So it shares some similarity. 
Kawanaka et al. [17] suggested the ratio of the HIF-2α 
positive cell in tumor infiltrative macrophages may be a new 
predictive indicator for prognosis. Our study also solidified 
that HIF-2α staining may be a key in radioresistance in 
cervical cancer.
In our study, we did not demonstrate a strong relationship 
between IS and radioresistance. However, staining may 
change subjectively, thus a more accurate in vitro test and 
more samples are needed to confirm the relationship.
 Although HIF-2α PS was related with PFS, the hazard ratio 
of IS and PS did not meet the criteria of the previous study.
CONFLICT OF INTEREST
No potential conflict of interest relevant to this article was 
reported.
Table 1. Patient characteristics
Characteristics Radiation-
resistant (n=12)
Radiation-
sensitive (n=24) p-value
Age (mean)  (62) (60) 0.17
    <50   2   4
    ≥50                              10 20
Stage 0.86
    IIB   6 14
    IIIB   5   8
    IVA   1   2
Cell type
    Squamous cell 12 24
Primary treatment
    RT 11 19
    CCRT 1* 5
†
Median PFS,
  mo (range)
7.8 (0-16) 70.0 (24-100) 0.02
RT: radiation therapy, CCRT: concurrent chemoradiation therapy, PFS: 
progression free survival, FU: fluorouracil. 
*Cisplatin+5FU. 
†Cisplatin+5FU (n=4) and weekly Cisplatin (n=1).
Table 2. Immunohistochemical analysis of HIF-2α expression in 
radiation-sensitive and radiation-resistant cervical cancer tissues 
HIF-2α staining IS Total
(n=36) 0 1+ 2+ 3+
Radiation-sensitive 6 11 6 1 24
Radiation-resistant 1   5 4 2 12
HIF: hypoxia inducible factor, IS: intensity score.
Table 4. Relationship between HIF-2α PS and hazard ratio of recurrence
HR (95% CI) p-value 
HIF-2α PS (I unit) 1.041 (1.014-1.074) <0.05
HIF-2α PS (10 units) 1.525 (1.144-2.033) <0.05
HIF: hypoxia inducible factor, PS: proportion score, HR: hazard ratio, 
CI: confidence interval.
Table 3. Distribution of HIF-2 α staining in two groups
Characteristics Radiation-resistant
(n=12)
Radiation-sensitive
(n=24) p-value
HIF-2α IS 1.5 (0-3) 1.0 (0-3)      0.133
HIF-2α PS 28.8 (0-80) 12.5 (0-40) <0.05
HIF: hypoxia inducible factor, IS: intensity score, PS: proportion score.Min Kyu Kim, et al.
48 www.ejgo.org DOI:10.3802/jgo.2011.22.1.44
REFERENCES
1.  Petignat P, Roy M. Diagnosis and management of cervical 
cancer. BMJ 2007;335:765-8.
2.  Hockel M, Vorndran B, Schlenger K, Baussmann E, 
Knapstein PG. Tumor oxygenation: a new predictive 
parameter in locally advanced cancer of the uterine 
cervix. Gynecol Oncol 1993;51:141-9.
3.  Hockel M, Schlenger K, Mitze M, Schaffer U, Vaupel P. 
Hypoxia and radiation response in human tumors. Semin 
Radiat Oncol 1996;6:3-9.
4.  Sutherland RM, Ausserer WA, Murphy BJ, Laderoute 
KR. Tumor hypoxia and heterogeneity: challenges 
and opportunities for the future. Semin Radiat Oncol 
1996;6:59-70.
5.  Brown JM, Wilson WR. Exploiting tumour hypoxia in 
cancer treatment. Nat Rev Cancer 2004;4:437-47.
6.  Thomlinson RH, Gray LH. The histological structure of 
some human lung cancers and the possible implications 
for radiotherapy. Br J Cancer 1955;9:539-49.
7.  Ishikawa H, Sakurai H, Hasegawa M, Mitsuhashi N, 
Takahashi M, Masuda N, et al. Expression of hypoxic-
inducible factor 1alpha predicts metastasis-free survival 
after radiation therapy alone in stage IIIB cervical 
squamous cell carcinoma. Int J Radiat Oncol Biol Phys 
2004;60:513-21.
8.  Koukourakis MI, Giatromanolaki A, Sivridis E, Simopoulos 
C, Turley H, Talks K, et al. Hypoxia-inducible factor (HIF1A 
and HIF2A), angiogenesis, and chemoradiotherapy 
outcome of squamous cell head-and-neck cancer. Int J 
Radiat Oncol Biol Phys 2002;53:1192-202.
9.  Gordan JD, Bertout JA, Hu CJ, Diehl JA, Simon MC. HIF-
2alpha promotes hypoxic cell proliferation by enhancing 
c-myc transcriptional activity. Cancer Cell 2007;11:335-47.
10.  Moeller BJ, Dreher MR, Rabbani ZN, Schroeder T, Cao Y, Li 
CY, et al. Pleiotropic effects of HIF-1 blockade on tumor 
radiosensitivity. Cancer Cell 2005;8:99-110.
11.  Bertout JA, Majmundar AJ, Gordan JD, Lam JC, Ditsworth 
D, Keith B, et al. HIF2alpha inhibition promotes p53 
pathway activity, tumor cell death, and radiation 
responses. Proc Natl Acad Sci U S A 2009;106:14391-6.
12.  Palayoor ST, Burgos MA, Shoaibi A, Tofilon PJ, Coleman 
CN. Effect of radiation and ibuprofen on normoxic renal 
carcinoma cells overexpressing hypoxia-inducible factors 
by loss of von Hippel-Lindau tumor suppressor gene 
function. Clin Cancer Res 2004;10:4158-64.
13.  Franovic A, Holterman CE, Payette J, Lee S. Human 
cancers converge at the HIF-2alpha oncogenic axis. Proc 
Natl Acad Sci U S A 2009;106:21306-11.
14.  Hutchison GJ, Valentine HR, Loncaster JA, Davidson 
SE, Hunter RD, Roberts SA, et al. Hypoxia-inducible 
factor 1alpha expression as an intrinsic marker of 
hypoxia: correlation with tumor oxygen, pimonidazole 
measurements, and outcome in locally advanced 
carcinoma of the cervix. Clin Cancer Res 2004;10:8405-12.
15.  Bachtiary B, Schindl M, Potter R, Dreier B, Knocke 
TH, Hainfellner JA, et al. Overexpression of hypoxia-
inducible factor 1alpha indicates diminished response 
to radiotherapy and unfavorable prognosis in patients 
receiving radical radiotherapy for cervical cancer. Clin 
Cancer Res 2003;9:2234-40.
16.  Burri P, Djonov V, Aebersold DM, Lindel K, Studer U, 
Altermatt HJ, et al. Significant correlation of hypoxia-
inducible factor-1alpha with treatment outcome in 
cervical cancer treated with radical radiotherapy. Int J 
Radiat Oncol Biol Phys 2003;56:494-501.
17.  Kawanaka T, Kubo A, Ikushima H, Sano T, Takegawa 
Y, Nishitani H. Prognostic significance of HIF-2alpha 
expression on tumor infiltrating macrophages in patients 
with uterine cervical cancer undergoing radiotherapy. J 
Med Invest 2008;55:78-86.
18.  Nakano T, Kato S, Ohno T, Tsujii H, Sato S, Fukuhisa K, 
et al. Long-term results of high-dose rate intracavitary 
brachytherapy for squamous cell carcinoma of the uterine 
cervix. Cancer 2005;103:92-101.
19.  Lee SY, Chung SM. Neovastat (AE-941) inhibits the airway 
inflammation via VEGF and HIF-2 alpha suppression. 
Vascul Pharmacol 2007;47:313-8.
20.  Freitas S, Moore DH, Michael H, Kelley MR. Studies of 
apurinic/apyrimidinic endonuclease/ref-1 expression 
in epithelial ovarian cancer: correlations with tumor 
progression and platinum resistance. Clin Cancer Res 
2003;9:4689-94.
21.  Moeller BJ, Cao Y, Li CY, Dewhirst MW. Radiation activates 
HIF-1 to regulate vascular radiosensitivity in tumors: 
role of reoxygenation, free radicals, and stress granules. 
Cancer Cell 2004;5:429-41.